These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

674 related articles for article (PubMed ID: 25047676)

  • 1. HER2 status in lung adenocarcinoma: a comparison of immunohistochemistry, fluorescence in situ hybridization (FISH), dual-ISH, and gene mutations.
    Yoshizawa A; Sumiyoshi S; Sonobe M; Kobayashi M; Uehara T; Fujimoto M; Tsuruyama T; Date H; Haga H
    Lung Cancer; 2014 Sep; 85(3):373-8. PubMed ID: 25047676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MET amplification, protein expression, and mutations in pulmonary adenocarcinoma.
    Park S; Koh J; Kim DW; Kim M; Keam B; Kim TM; Jeon YK; Chung DH; Heo DS
    Lung Cancer; 2015 Dec; 90(3):381-7. PubMed ID: 26791796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The frequency and clinical impact of HER2 alterations in lung adenocarcinoma.
    Kim EK; Kim KA; Lee CY; Shim HS
    PLoS One; 2017; 12(2):e0171280. PubMed ID: 28146588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lung adenocarcinomas with HER2-activating mutations are associated with distinct clinical features and HER2/EGFR copy number gains.
    Li C; Sun Y; Fang R; Han X; Luo X; Wang R; Pan Y; Hu H; Zhang Y; Pao W; Shen L; Ji H; Chen H
    J Thorac Oncol; 2012 Jan; 7(1):85-9. PubMed ID: 22071781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-existence of positive MET FISH status with EGFR mutations signifies poor prognosis in lung adenocarcinoma patients.
    Tanaka A; Sueoka-Aragane N; Nakamura T; Takeda Y; Mitsuoka M; Yamasaki F; Hayashi S; Sueoka E; Kimura S
    Lung Cancer; 2012 Jan; 75(1):89-94. PubMed ID: 21733594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use?
    Park YS; Hwang HS; Park HJ; Ryu MH; Chang HM; Yook JH; Kim BS; Jang SJ; Kang YK
    Hum Pathol; 2012 Mar; 43(3):413-22. PubMed ID: 21855114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis.
    Thomas A; Chen Y; Steinberg SM; Luo J; Pack S; Raffeld M; Abdullaev Z; Alewine C; Rajan A; Giaccone G; Pastan I; Miettinen M; Hassan R
    Oncotarget; 2015 May; 6(13):11694-703. PubMed ID: 26028668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER2 status in patients with residual rectal cancer after preoperative chemoradiotherapy: the relationship with molecular results and clinicopathologic features.
    Park JS; Yoon G; Kim HJ; Park SY; Choi GS; Kang MK; Kim JG; Jang JS; Seo AN
    Virchows Arch; 2018 Oct; 473(4):413-423. PubMed ID: 30056472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers.
    Li BT; Ross DS; Aisner DL; Chaft JE; Hsu M; Kako SL; Kris MG; Varella-Garcia M; Arcila ME
    J Thorac Oncol; 2016 Mar; 11(3):414-9. PubMed ID: 26723242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of epidermal growth factor receptor and human epidermal growth factor receptor 2 activating mutations in lung adenocarcinoma by high-resolution melting amplicon analysis: correlation with gene copy number, protein expression, and hormone receptor expression.
    Willmore-Payne C; Holden JA; Layfield LJ
    Hum Pathol; 2006 Jun; 37(6):755-63. PubMed ID: 16733218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER2 expression and markers of phosphoinositide-3-kinase pathway activation define a favorable subgroup of metastatic pulmonary adenocarcinomas.
    Reis H; Herold T; Ting S; Worm K; Huber U; Christoph DC; Eberhardt WE; Kostbade K; Kasper S; Stamatis G; Welter S; Darwiche K; Karpf-Wissel R; Theegarten D; Schmid KW; Schuler M; Wiesweg M
    Lung Cancer; 2015 Apr; 88(1):34-41. PubMed ID: 25708529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas.
    Anglesio MS; Kommoss S; Tolcher MC; Clarke B; Galletta L; Porter H; Damaraju S; Fereday S; Winterhoff BJ; Kalloger SE; Senz J; Yang W; Steed H; Allo G; Ferguson S; Shaw P; Teoman A; Garcia JJ; Schoolmeester JK; Bakkum-Gamez J; Tinker AV; Bowtell DD; Huntsman DG; Gilks CB; McAlpine JN
    J Pathol; 2013 Jan; 229(1):111-20. PubMed ID: 22899400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation and workflow optimization of human epidermal growth factor receptor 2 testing using INFORM HER2 dual-color in situ hybridization.
    Lim SJ; Cantillep A; Carpenter PM
    Hum Pathol; 2013 Nov; 44(11):2590-6. PubMed ID: 24075600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of HER2 status between surgically resected specimens and matched biopsy specimens of gastric intestinal-type adenocarcinoma.
    Yoshida H; Yamamoto N; Taniguchi H; Oda I; Katai H; Kushima R; Tsuda H
    Virchows Arch; 2014 Aug; 465(2):145-54. PubMed ID: 24889042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of fluorescence in situ hybridization (FISH) and dual-ISH (DISH) in the determination of HER2 status in breast cancer.
    Mansfield AS; Sukov WR; Eckel-Passow JE; Sakai Y; Walsh FJ; Lonzo M; Wiktor AE; Dogan A; Jenkins RB
    Am J Clin Pathol; 2013 Feb; 139(2):144-50. PubMed ID: 23355198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of comprehensive genomic sequencing for detecting HER2-positive colorectal cancer.
    Shimada Y; Yagi R; Kameyama H; Nagahashi M; Ichikawa H; Tajima Y; Okamura T; Nakano M; Nakano M; Sato Y; Matsuzawa T; Sakata J; Kobayashi T; Nogami H; Maruyama S; Takii Y; Kawasaki T; Homma KI; Izutsu H; Kodama K; Ring JE; Protopopov A; Lyle S; Okuda S; Akazawa K; Wakai T
    Hum Pathol; 2017 Aug; 66():1-9. PubMed ID: 28235632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas.
    Mescam-Mancini L; Lantuéjoul S; Moro-Sibilot D; Rouquette I; Souquet PJ; Audigier-Valette C; Sabourin JC; Decroisette C; Sakhri L; Brambilla E; McLeer-Florin A
    Lung Cancer; 2014 Feb; 83(2):168-73. PubMed ID: 24380695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concurrence of EGFR amplification and sensitizing mutations indicate a better survival benefit from EGFR-TKI therapy in lung adenocarcinoma patients.
    Shan L; Wang Z; Guo L; Sun H; Qiu T; Ling Y; Li W; Li L; Liu X; Zheng B; Lu N; Ying J
    Lung Cancer; 2015 Sep; 89(3):337-42. PubMed ID: 26141217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER2 gene mutations in non-small cell lung carcinomas: concurrence with Her2 gene amplification and Her2 protein expression and phosphorylation.
    Suzuki M; Shiraishi K; Yoshida A; Shimada Y; Suzuki K; Asamura H; Furuta K; Kohno T; Tsuta K
    Lung Cancer; 2015 Jan; 87(1):14-22. PubMed ID: 25468202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER2 Status in Gastroesophageal Adenocarcinomas: Correlation Between Immunohistochemistry and Fluorescence In Situ Hybridization Methodologies.
    Robertson SA; Cimino-Mathews A; Cornish TC
    Appl Immunohistochem Mol Morphol; 2018 Jan; 26(1):35-39. PubMed ID: 27153447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.